Trials / Unknown
UnknownNCT04833322
Galactose Supplementation for the Treatment of MOGHE
Galactose Supplementation for the Treatment of Patients With Mild Malformation of Cortical Development With Oligodendroglial Hyperplasia in Epilepsy (MOGHE): a Pilot Trial
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 8 (estimated)
- Sponsor
- Hospital Ruber Internacional · Academic / Other
- Sex
- All
- Age
- 2 Years – 20 Years
- Healthy volunteers
- Not accepted
Summary
Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE) is a new entity frequently associated with refractory epilepsy and neurodevelopmental disorders. Recently, it has been associated to SLC35A2 (Solute Carrier Family 35 Member A2) brain mosaic pathogenic variants. In addition, patients with germline SLC35A2 pathogenic variants improve with galactose supplementation. Therefore, the investigators aim to elucidate whether d-galactose as an add-on treatment might improve epilepsy and developmental outcomes in patients with MOGHE.
Conditions
- Refractory Epilepsy
- SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | D-Galactose | Galactose supplementation, once per day, up to 1.5g/kg per day |
Timeline
- Start date
- 2021-01-15
- Primary completion
- 2021-09-01
- Completion
- 2021-10-01
- First posted
- 2021-04-06
- Last updated
- 2021-04-06
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT04833322. Inclusion in this directory is not an endorsement.